Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Vilanterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 26 Apr 2018 Status changed from active, no longer recruiting to completed.
- 09 Apr 2018 This trial has been completed in Spain, according to European Clinical Trials Database
- 01 Mar 2018 Planned End Date changed from 21 Mar 2018 to 23 Apr 2018.